Dana-Farber Investigators Report Promising Results from Phase 2 Study of Targeted Therapy for Rare Bile Duct Cancer
July 01, 2026
July 01, 2026
BOSTON, Massachusetts, July 1 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:
* * *
Dana-Farber Investigators Report Promising Results from Phase 2 Study of Targeted Therapy for Rare Bile Duct Cancer
* Patients with advanced NRG1-positive cholangiocarcinoma showed promising responses to zenocutuzumab, a bispecific antibody.
* Based on this evidence, the FDA approved zenocutuzmab on May 8 for NRG1 . . .
* * *
Dana-Farber Investigators Report Promising Results from Phase 2 Study of Targeted Therapy for Rare Bile Duct Cancer
* Patients with advanced NRG1-positive cholangiocarcinoma showed promising responses to zenocutuzumab, a bispecific antibody.
* Based on this evidence, the FDA approved zenocutuzmab on May 8 for NRG1 . . .